FOS expression in blood as a LDL-independent marker of statin treatment

Ju Gyeong Kang, Ho Joong Sung, Sarah I. Jawed, Cynthia L. Brenneman, Yesoda N. Rao, Salman Sher, Flavia M. Facio, Leslie G. Biesecker, Arshed A. Quyyumi, Vandana Sachdev, Paul M. Hwang

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


Objectives: The expression of FOS, a gene critical for monocyte and macrophage function, can be inhibited by statins through the disruption of a cholesterol-independent signaling pathway. In this pilot study, we hypothesized that blood FOS mRNA levels will be sensitive to statin treatment independent of LDL cholesterol levels. Methods: Three cohorts at increased risk of or with cardiovascular disease (CVD) were studied. Blood FOS mRNA levels were measured before and after statin treatment or in patients under stable treatment. Results: Statin treatment for three months significantly reduced blood FOS mRNA and LDL cholesterol levels. However, in subjects with similar LDL levels achieved by different doses of long term statin treatment, there was an inverse relationship between statin dose and FOS expression. Conclusions: FOS mRNA levels appear to be a sensitive marker of statin treatment that is dissociated from cholesterol levels.

Original languageEnglish (US)
Pages (from-to)567-570
Number of pages4
Issue number2
StatePublished - Oct 2010
Externally publishedYes


  • Atherosclerosis
  • Biomarker
  • Blood
  • FOS
  • Gene expression
  • Inflammation
  • Macrophage
  • Monocyte
  • Pleiotropic
  • Statin

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'FOS expression in blood as a LDL-independent marker of statin treatment'. Together they form a unique fingerprint.

Cite this